Human EGFR-Del19/T790M/C797S Stable Cell Line - PC-9

The discovery of EGFR mutations, particularly EGFR-Del19, T790M, and C797S, has revolutionized the management of non-small cell lung cancer (NSCLC), offering critical insights into tumor biology and therapeutic strategies. EGFR-Del19, first identified in the early 2000s, involves the deletion of amino acids 747 to 750 in exon 19 of the EGFR gene. This alteration leads to increased kinase activity and heightened sensitivity to EGFR tyrosine kinase inhibitors (TKIs) like gefitinib and erlotinib. However, the emergence of resistance remains a significant challenge in EGFR-mutant NSCLC.

The T790M mutation, occurring in approximately half of patients who develop resistance to first-generation EGFR TKIs, involves a substitution of threonine with methionine at position 790 within the EGFR kinase domain. This alteration impairs TKI binding while maintaining EGFR activation, rendering tumors resistant to therapy. Subsequently, third-generation EGFR TKIs, such as osimertinib, were developed to target T790M-positive tumors, yet the emergence of additional mutations, notably C797S, poses further obstacles.

C797S mutation arises within the kinase domain of EGFR and disrupts the covalent binding of third-generation TKIs, leading to treatment resistance. Its identification underscores the dynamic nature of tumor evolution and the necessity for ongoing therapeutic innovation. In response, researchers have utilized sophisticated genetic engineering techniques to establish cell line models harboring EGFR-Del19, T790M, and C797S mutations, such as the Human EGFR-Del19/T790M/C797S Stable Cell Line - PC-9. These models serve as invaluable tools for elucidating mechanisms of drug resistance, evaluating novel treatment modalities, and guiding personalized therapeutic approaches in EGFR-mutant NSCLC patients.